
IGF-1 LR3
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid analog of insulin-like growth factor 1, engineered with an extra N-terminal extension and an arginine substitution. These changes dramatically reduce its binding to IGF-binding proteins, giving it far greater potency and a longer active life than native IGF-1.
| Test | Result | Status |
|---|---|---|
| Purity | 99.6% | Passed ✓ |
| Test | Result | Status |
|---|---|---|
| Purity | 98.9% | Passed ✓ |
Research Information
IGF-1 LR3 is studied for its potent activation of the IGF-1 receptor and downstream PI3K/Akt and MAPK signaling, driving cell proliferation, differentiation and anabolic pathways. Because it evades binding-protein sequestration, it is a favored tool for studying sustained IGF-1 signaling in cell-culture and animal models. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.
IGF-1 LR3 Research & Studies
What is IGF-1 LR3?
IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid analog of insulin-like growth factor 1 engineered with an extended N-terminal sequence and an arginine substitution at position 3. These structural modifications markedly reduce affinity for IGF-binding proteins relative to native IGF-1. In laboratory settings the compound is examined as a research tool for probing prolonged IGF-1 receptor engagement. It is supplied strictly for in-vitro and controlled laboratory research use only.
Mechanism of Action
IGF-1 LR3 is studied for its high-affinity interaction with the IGF-1 receptor, triggering receptor autophosphorylation and recruitment of adaptor proteins. Downstream cascades under investigation include the PI3K/Akt pathway, linked to metabolic and survival signaling, and the MAPK/ERK pathway, associated with proliferative responses. Because the analog largely escapes sequestration by IGF-binding proteins, experimental systems can maintain elevated free ligand levels for extended observation of these cascades.
Primary Areas of Research
Investigators employ IGF-1 LR3 to examine cell proliferation, differentiation, and anabolic signaling networks in cultured mammalian cells and selected animal models. Research focuses on how sustained IGF-1 receptor activation influences protein synthesis machinery, cell-cycle progression, and tissue-specific growth pathways. The compound is also used to dissect differences between transient versus prolonged ligand exposure in receptor trafficking and desensitization studies.
Key Research Findings
Published laboratory work indicates that IGF-1 LR3 produces more durable IGF-1 receptor stimulation than equimolar native IGF-1 under identical culture conditions, attributable to reduced IGFBP binding. Model systems consistently show robust activation of Akt and MAPK phosphorylation when the analog is present. These observations have made IGF-1 LR3 a preferred reagent for experiments requiring continuous pathway drive without frequent media replenishment.
Structural Features and Stability
The N-terminal extension and Arg3 substitution of IGF-1 LR3 alter surface contacts that normally mediate high-affinity IGFBP interaction. In buffered aqueous solutions the peptide retains receptor-binding competence longer than native IGF-1, facilitating multi-day cell-culture protocols. Researchers document these properties when designing time-course and dose-response experiments that compare analog versus wild-type ligand behavior.
Research Handling and Considerations
IGF-1 LR3 is handled under standard peptide laboratory practices, including cold-chain storage and reconstitution in appropriate sterile buffers for cell-culture or in-vitro assays. Investigators verify lot-specific purity and concentration by analytical methods before experimental use. All work remains confined to controlled research environments; the material is not intended for human or animal administration.
Frequently Asked Questions
The N-terminal extension and Arg3 substitution greatly reduce IGFBP binding, allowing longer free-ligand exposure and more sustained receptor activation in cell-culture and animal-model studies.
Explore Other High-Purity Peptides

Ipamorelin

CJC-1295 (No DAC)

Sermorelin
